The earnings call highlighted significant progress in clinical trials and strategic partnerships, strengthening Absci's financial position and enhancing its drug development capabilities. However, the increase in R&D expenses and low revenue figures present challenges that need to be addressed.

Company Guidance

During Absci's Second Quarter 2025 Business Update Call, the company provided significant guidance on its financial and operational progress. The call highlighted multiple key metrics, including the initiation of Phase I clinical trials for ABS-101, with interim results anticipated later this year, and plans for ABS-201 to enter Phase I/IIa trials in early 2026. The company reported second-quarter revenue of $600,000, with research and development expenses increasing to $20.5 million from $15.3 million year-over-year, while selling, general, and administrative expenses decreased to $8.5 million. Absci strengthened its financial position by raising approximately $64 million, bringing its cash, cash equivalents, and short-term investments to $117.5 million as of June 30, 2025, ensuring operations are funded into the first half of 2028. Management reiterated the strategic focus on out-licensing and partnering programs, with an anticipated drug creation partnership with a large pharma company expected this year. The company is also advancing its AI-driven drug creation platform, supported by a $20 million strategic investment from AMD.

Initiation of Phase I Clinical Trials for ABS-101

Absci began Phase I clinical trials for ABS-101, a potential best-in-class anti-TL1A antibody, with plans to report interim results later in the year.

Progress on ABS-201 Program

ABS-201, an innovative antip-prolactin receptor antibody for androgenetic alopecia, is advancing rapidly towards clinical trials, offering potential breakthrough in hair regrowth therapy.

Strategic Investment by AMD

AMD made a $20 million strategic investment in Absci, supporting the development of Absci's AI-driven drug creation platform.

Successful Capital Raise

Absci raised approximately $64 million in gross proceeds to strengthen the balance sheet, extending cash runway into the first half of 2028.

Expansion with Almirall Partnership

Almirall collaboration advanced to include a second program with potential milestone payments totaling approximately $650 million.

AbSci (ABSI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ABSI Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.20 / -	-0.24	―	―	―
Aug 12, 2025	2025 (Q2)	-0.21 / -0.24	-0.22	-9.09% (-0.02)	―
May 13, 2025	2025 (Q1)	-0.22 / -0.21	-0.22	4.55% (+0.01)	―
Mar 18, 2025	2024 (Q4)	-0.22 / -0.25	-0.25	0.00% (0.00)	―
Nov 12, 2024	2024 (Q3)	-0.19 / -0.24	-0.24	0.00% (0.00)	―
Aug 14, 2024	2024 (Q2)	-0.18 / -0.22	-0.45	51.11% (+0.23)	―
May 14, 2024	2024 (Q1)	-0.21 / -0.22	-0.26	15.38% (+0.04)	―
Mar 21, 2024	2023 (Q4)	-0.21 / -0.25	-0.21	-19.05% (-0.04)	―	―
Nov 14, 2023	2023 (Q3)	-0.23 / -0.24	-0.3	20.00% (+0.06)	―	―
Aug 14, 2023	2023 (Q2)	-0.24 / -0.45	-0.32	-40.63% (-0.13)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ABSI Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 12, 2025	$2.97	$3.12	+5.05%
May 13, 2025	$2.96	$2.91	-1.69%
Mar 18, 2025	$3.08	$2.98	-3.25%
Nov 12, 2024	$4.28	$3.64	-14.95%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does AbSci (ABSI) report earnings?

AbSci (ABSI) is schdueled to report earning on Nov 05, 2025, Before Open (Confirmed).

What is AbSci (ABSI) earnings time?

AbSci (ABSI) earnings time is at Nov 05, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ABSI EPS forecast?

ABSI EPS forecast for the fiscal quarter 2025 (Q3) is -0.2.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing